CVS Chart

1 Month

	Date	Diff	Articles
	2025-05-02	-2.87 %	CVS Health (CVS) stock fell by 2.87% amid positive economic indicators lifting the broader stock market and concerns arising from its partnership with Novo Nordisk to distribute the Wegovy weight-loss drug at lower prices, which has created apprehension among Eli Lilly investors.
CVS Health (CVS) stock fell by 2.87% amid positive economic indicators lifting the broader stock market and concerns arising from its partnership with Novo Nordisk to distribute the Wegovy weight-loss drug at lower prices, which has created apprehension among Eli Lilly investors. The article discusses the significant decline of CVS Health (CVS) stock, which fell by 2.87%, while also promoting Bliss CBD Gummies as a health supplement that provides stress relief and improves well-being. CVS Health (CVS) stock may have decreased due to various factors such as market fluctuations, investor concerns about company performance, or broader economic conditions, but these specifics are not detailed in the article. CVS Health (CVS) stock fell 2.87% due to market concerns over a deal between CVS and Novo Nordisk that excludes Eli Lilly's weight-loss drug from its formulary, which could lead to increased competition and reduced profit margins in the GLP-1 medication market.
	2025-05-01	+4.11 %	CVS Health's stock rose by 4.11% due to its announcement that it would include rival weight-loss drugs Wegovy and Saxenda on its preferred formulary while excluding Eli Lilly's Zepbound, potentially increasing the accessibility of these medications and enhancing CVS's market competitiveness.
CVS Health's stock rose by 4.11% due to its announcement that it would include rival weight-loss drugs Wegovy and Saxenda on its preferred formulary while excluding Eli Lilly's Zepbound, potentially increasing the accessibility of these medications and enhancing CVS's market competitiveness. CVS Health's stock rose 4.11% after the company reported strong first-quarter results that exceeded expectations and raised its full-year adjusted earnings per share outlook, despite a lowered overall EPS forecast due to one-time factors. CVS Health (CVS) shares surged 7% following the release of its strong first-quarter financial results, which exceeded analyst expectations with a 7% year-over-year revenue increase to $94.59 billion and a more than 70% rise in adjusted EPS to $2.25, despite a cautious outlook for the year due to potential macroeconomic challenges. CVS Health stock increased by 4.11% amid a broader market rally driven by strong earnings reports from major companies like Microsoft and Meta Platforms, which boosted investor sentiment and confidence in the market. CVS Health's stock rose 4.11% following the company's announcement of a higher-than-expected 2025 earnings forecast, driven by improved Medicare benefits and better star ratings for its Medicare Advantage plans, leading to a 60% increase in profit for the first quarter.
	2025-04-30	+2.58 %	CVS Health (CVS) stock rose 2.58% ahead of its upcoming earnings report, driven by positive analyst expectations for a significant year-over-year earnings increase and strong recent stock performance, despite bearish sentiment in options trading that may lead to a contrarian rally if earnings exceed projections.
CVS Health (CVS) stock rose 2.58% ahead of its upcoming earnings report, driven by positive analyst expectations for a significant year-over-year earnings increase and strong recent stock performance, despite bearish sentiment in options trading that may lead to a contrarian rally if earnings exceed projections.